NCT00547066 - Study of Veltuzumab (hA20) at Different Doses in Patients With ITP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Purpura, Thrombocytopenic, IdiopathicAutoimmune Thrombocytopenic PurpuraPurpura, Thrombocytopenic, Autoimmune

Interventions

BIOLOGICAL

veltuzumab

hA20 will be administered intravenously in two doses over two weeks

Trial Locations (8)

New York Presbyterian Hospital Weill Cornell Medical Center, New York

Hematology/Oncology Specialists, Buffalo

Georgia Cancer Specialtists, Tucker

Center of Hope for Cancer and Blood Disorders, Riverdale

Goshen Center for Cancer Care, Goshen

Hematology Oncology Specialists, Metairie

University of Southern California- Keck School of Medicine, Los Angeles

Denville